8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): December 12, 2016

REVANCE THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

DELAWARE	001-36297	75-0551645
(State of incorporation)	(Commission File No.)	(IRS Employer Identification No.)

Revance Therapeutics, Inc.

7555 Gateway Boulevard

Newark, California 94560

(Address of principal executive offices and zip code)

Registrant’s telephone number, including area code: (510) 742-3400

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

ITEM 7.01 REGULATION FD DISCLOSURE.

As reported under Item 8.01 of this current report on Form 8-K, Revance Therapeutics, Inc. (the “Company”) issued a press release on December 12, 2016 announcing positive results from its Phase 2 open-label, dose-escalating clinical study to evaluate the safety and preliminary efficacy of its investigational drug product candidate, DaxibotulinumtoxinA for Injection (RT002) for the treatment of cervical dystonia, a muscle movement disorder. During a conference call and webcast scheduled to be held at 4:30 PM Eastern Time on December 12, 2016, Company management will discuss the results from the study. The slide presentation for the conference call and webcast is furnished as Exhibit 99.1 hereto and is incorporated by reference herein. A copy of the press release is furnished as Exhibit 99.2 hereto and is incorporated by reference herein.

The furnishing of the attached presentation is not an admission as to the materiality of any information therein. The information contained in the slides is summary information that is intended to be considered in the context of more complete information included in the Company’s filings with the Securities and Exchange Commission (the “SEC”) and other public announcements that the Company has made, including the press release furnished as Exhibit 99.2 hereto, and may make from time to time by press release or otherwise.

The information in this Item 7.01 of this current report on Form 8-K and Exhibits 99.1 and 99.2 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in any such filing.

ITEM 8.01 OTHER EVENTS

On December 12, 2016, the Company announced positive results from its Phase 2 open-label, dose-escalating clinical study to evaluate the safety and preliminary efficacy of RT002 injectable for the treatment of cervical dystonia. The topline interim data showed that RT002 injectable appeared to be generally safe and well-tolerated, demonstrated median duration of >24 weeks, and displayed clinically significant impact on cervical dystonia signs and symptoms. The trial enrolled 37 subjects and follows three sequential treatment cohorts for up to a total of 24 weeks after treatment for each cohort. The trial’s first cohort of 12 subjects received a single dose of up to 200 units of RT002 injectable, the second cohort of 12 subjects received between 200 and 300 units, and the third cohort received from 300 to 450 units. Later-enrolled subjects in the second and third cohorts have yet to complete the trial’s 24-week protocol. Today’s results are therefore preliminary, with final results expected in the first half of 2017.

Key interim results of the cervical dystonia trial are as follows:

• SAFETY: In all three cohorts, RT002 injectable appeared to be generally safe and well-tolerated. There were no serious adverse events and no dose-dependent increase in adverse events. The treatment-related adverse events were transient and mild to moderate in severity, except for one case of neck pain reported as severe, with a duration of 2 days. The most common adverse events were dysphagia, or difficulty in swallowing (10.8%), injection site redness (8.1%), injection site pain (5.4%), muscle tightness (5.4%) and muscle weakness (5.4%). For reference, trials for botulinum type A products approved to treat cervical dystonia have adverse events for dysphagia ranging from 13% to 39%.

• EFFICACY: The trial’s 4-week primary efficacy measurement was the improvement in dystonia symptoms as determined by reduction from baseline on the Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS)-Total score. RT002 injectable showed a clinically significant mean reduction of 16.9 from baseline, or 38%, across all three cohorts. In cohort one, with a mean dose of 174 units, the majority of the 44% reduction observed in the TWSTRS-Total score at Week 4 was preserved at Week 24, with a 33% mean reduction from baseline observed. Clinically meaningful mean reductions in the TWSTRS Severity, Disability and Pain subscales were consistent and observed at all follow-up visits in the first cohort. Later-enrolled subjects in the second and third cohorts have not yet reached the 24-week point. For reference, placebo-controlled trials with botulinum type A products approved to treat cervical dystonia had a reduction in the TWSTRS-Total score from baseline of 14% to 26% at Week 4.

• DURATION OF EFFECT: Duration of effect for this trial was defined as the number of weeks from treatment until the return of symptoms that warrant retreatment, based on the subject’s target TWSTRS score. The median duration of effect was at least 24 weeks for subjects in cohort one (n=12), and at least 16 weeks for subjects in cohort two (n=11), using the complete 16 week follow up data. In cohort one, no subjects had returned to baseline at Week 24 and only one subject in cohort two, to date, has returned to baseline, which occurred at the Week 24 visit. In cohort one, RT002 achieved a median duration of at least 24 weeks based on three different assessments, including 1) the number of weeks from treatment until a subject reaches or exceeds their target TWSTRS-Total score, 2) improvement (score >0) on the Clinician Global Impression of Change (CGIC), and 3) TWSTRS-Total score return to baseline. For reference, current treatment of cervical dystonia calls for injection of botulinum toxin approximately every 3 months, or 4 times per year.

The Company also has recently enrolled patients in its Phase 3 SAKURA clinical trial of RT002 injectable for the treatment of moderate to severe glabellar lines in adults and initiated a Phase 2 placebo-controlled trial of RT002 injectable for the management of plantar fasciitis. Results for both studies are expected in 2017.

ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS

(d) Exhibits.

Number	Description
99.1	Company slide presentation dated December 12, 2016.
99.2	Press Release dated December 12, 2016.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: December 12, 2016	Revance Therapeutics, Inc.
	By:	/s/ Lauren P. Silvernail
		Lauren P. Silvernail
		Executive Vice President, Corporate Development and Chief Financial Officer

EXHIBIT INDEX

Number	Description
99.1	Company slide presentation dated December 12, 2016.
99.2	Press Release dated December 12, 2016.

EX-99.1

Revance TherapeutIcs DaxibotulinumtoxinA for Injection (RT002) Investigational Product for the Treatment of Cervical Dystonia RT002 is an investigational product Interim Results for Phase 2 Open-Label Study Exhibit 99.1

Forward-Looking Statements / Safe Harbor This presentation contains forward-looking statements, including statements related to: our financial outlook and other financial performance; the process and timing of anticipated future clinical development of our product candidates; our business strategy, goals, plans and prospects; timing and outcome of our clinical trials; our ability to obtain regulatory approval; the potential therapeutic and economic benefits and value of our product candidates and our technologies; demand for our product candidates and drivers of demand; market size, adoption rate and potential revenue; growth opportunities and product pipeline; our ability to leverage our investment in our development and manufacturing platform; and our intellectual property strategy. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from our expectations. These risks and uncertainties include, but are not limited to: the outcome, cost and timing of our product development activities and clinical trials; the uncertain clinical development process, including the risks that interim results are not indicative of final results and that that clinical trials may not have an effective design; our ability to obtain and maintain regulatory approval of our product candidates; our ability to obtain funding for our operations; our plans to research, develop and commercialize our product candidates; our ability to achieve market acceptance of our product candidates; unanticipated costs or delays in research, development and commercialization efforts; the applicability of clinical study results to actual outcomes; the size and growth potential of the markets for our product candidates; our ability to successfully commercialize our product candidates and the timing of commercialization activities; the rate and degree of market acceptance of our product candidates; our ability to develop sales and marketing capabilities; the accuracy of our estimates regarding expenses, future revenues, capital requirements and needs for financing; and our ability to continue obtaining and maintaining intellectual property protection for our product candidates. These and other risks are described in the “Risk Factors” section of our Form 10-Q filed with the Securities and Exchange Commission on November 4, 2016. The “Risk Factors” section of 10-Q speaks only as of the date thereof. These forward-looking statements speak only as of the date hereof or the date specified. Revance disclaims any obligation to update these forward-looking statements. “Revance Therapeutics”, TransMTS, “Remarkable Science Changes Everything”, and the Revance logo are registered trademarks of Revance Therapeutics, Inc. All other trademarks or registered trademarks are the property of their respective owners.

Study Objectives To assess the safety and preliminary efficacy of RT002 for Injection in subjects with isolated CD To evaluate the duration of effect of RT002 for Injection in the treatment of isolated CD Primary Endpoint: Improvement of dystonia, as measured by change from baseline in TWSTRS-Total score at Week 4 Secondary Endpoints: Change from baseline in TWSTRS-Total score Change from baseline in TWSTRS subscale scores: (i.e. TWSTRS-Severity Scale, TWSTRS-Disability Scale & TWSTRS-Pain Scale) Duration of effect, as assessed by the number of weeks from treatment until return of symptoms that warrant treatment, regarded as when a subject reaches or exceeds their target TWSTRS-Total score, or subject expresses a need for treatment and investigator agrees that it is necessary Percentage of responders showing improvement on CGIC Patient-rated quality of life, measured by change from baseline in CDIP-58 Total score (all post-treatment time points) Cervical Dystonia (CD) Phase 2 Study Objectives, Primary & Secondary Efficacy Endpoints TWSTRS: Toronto Western Spasmodic Torticollis Rating Scale; CGIC = Clinician Global Impression of Change; CDIP-58 = Cervical Dystonia Impact Profile-58

Cervical Dystonia (CD) Phase 2 Study Design RT002 up to 200 U Independent Data Monitoring Committee (iDMC) (6 week safety) iDMC (6 week safety) RT002 200 to 300 U RT002 300 to 450 U Eligibility Criteria: Patients with Moderate to Severe CD TWSTRS*-Total score ≥ 20 TWSTRS-Severity subscale ≥ 15 Cohort 1 (n=12) Completed 24 Weeks @ Interim Analysis (IA) Cohort 2 (n=12) Completed 16 Weeks @ IA Cohort 3 (n=13) Completed 4 Weeks @ IA * Toronto Western Spasmodic Torticollis Rating Scale

Demographics   Cohort 1 (N=12) Cohort 2 (N=12) Cohort 3 (n=13) All (n=37) Mean age (range) 57 (46--74) 52 (32--70) 58 (30--69) 56 (30--74) Females, n (%) 11 (92%) 8 (67%) 9 (69%) 28 (76%) Mean RT002 dose, U, (range) 174 (100--200) 229 (200--300) 323 (300--450) 244 (100--450) Mean CD Disease Duration, years, (range) 8.5 (0.4—21.7) 5.1 (0.0—24.1) 9.0 (0.6—23.3) 7.6 (0.0—24.1) Prior Treatment with BotulinumtoxinA 5 (42%) 4 (33%) 6 (46%) 15 (41%)

Treatment-Related Adverse Events ( > 2 Events) Preferred Term Cohort 1 (N=12) Cohort 2 (N=12) Cohort 3 (n=13) All (n=37) Subjects with treatment-related AEs, n (%) 6 (50%) 5 (41.7%) 2 (15.4%) 13 (35.1%) Total number of Treatment-related AEs* 8 8 4 20 Dysphagia 1 (8.3%) 2 (16.7%) 1 (7.7%) 4 (10.8%)† Injection site erythema 2 (16.7%) 0 1 (7.7%) 3 (8.1%) Injection site pain 0 1 (8.3%) 1 (7.7%) 2 (5.4%) Muscle tightness 0 1 (8.3%) 1 (7.7%) 2 (5.4%) Muscular weakness (Neck) 2 (16.7%) 0 0 2 (5.4%)‡ * Including AEs in only 1 event † All events mild in severity ‡1 mild, 1 moderate in severity Note: One case of severe neck pain reported; onset day 10, duration 2 days

Mean Baseline TWSTRS-Total Score and Subscales Error bars represent +1 SE. TWSTRS-Total Score

Primary Endpoint: Reduction in TWSTRS-Total Score at Week 4 by Cohort NOTE: 1) Two subjects currently on study had missing value at Week 4 for IA 38% 46% 28% 41% Clinically Meaningful Reduction in TWSTRS-Total Score Observed at Week 4 across all 3 Cohorts

Secondary Endpoint: Change from Baseline in TWSTRS-Total Score over Time 46% 43% 33% 28% 51% 27% 41% Clinically Meaningful Reduction in TWSTRS-Total Score Observed by Week 2 and Maintained to Week 24 for Cohort 1* 36% * Later-enrolled subjects in the second and third cohorts have yet to complete the trial’s 24-week protocol.

Median Duration Cohort 1 >24 weeks Cohort 1+2 >24 weeks* Cohort 2 Censored at 16 weeks *Cohort 1+2 analysis based on worse-outcome imputation for ongoing subjects Note: 1) Study discontinuation prior to Week 24 counted as an event. 2) Analysis for Cohort 2 censored at Week 16 as portion of subjects within cohort have yet to complete study. Secondary Endpoint: Duration of Response as Defined by Reaching / Exceeding Target-TWSTRS Score (of Subjects with Improvement at Week 4) Median Duration of Response > 24 Weeks for Cohort 1

Primary & Secondary Endpoints: Reduction in TWSTRS-Total Score and Subscales at Week 4 NOTE: Subjects with a missing value for either Baseline or Week 4 are excluded from the summary. 38% 34% 42% 41% Clinically Meaningful Reduction Observed across all 3 TWSTRS Subscales at Week 4

Secondary Endpoint: Proportion of Responders with Improvement in CGIC* (Score >0) by Visit * Clinician Global Impression of Change At Least 70% Response Rate at Week 16 Observed in Cohorts 1 and 2, with majority of benefit maintained in Cohort 1 subjects at Week 24 Note: Based on observed data only and n’s varied at each time point.

Secondary Endpoint: Change from Baseline in CDIP-58* over Time 25% 24% 41% 33% 30% 45% 32% * Cervical Dystonia Impact Profile-58 Quality of Life Measure Meaningful Improvement in Patient Rated Quality of Life Observed at Week 4, with Majority of Benefit Maintained in Cohort 1 at Week 24 Note: Based on observed data only and n’s varied at each time point. (n = 12) (n = 12) (n = 13)

Summary of Safety Results RT002 appeared to be generally safe and well tolerated across all 3 cohorts, with no increase in treatment-related AE’s upon dose escalation Total of 20 Treatment Related AE’s reported in 13 of 37 subjects Most frequently reported: dysphagia (10.8%), injection site erythema (8.1%) injection site pain (5.4%), muscle tightness (5.4%) and muscular weakness (5.4%) All Treatment Related AE’s were mild or moderate in severity except for one case of neck pain reported as severe (Day 10 onset, duration of 2 days) Trials of other BoNTA products approved to treat CD have rates of dysphagia ranging from 13-39%* No Serious AE’s were reported The following Treatment-Related AE’s associated with distant spread of toxin were not observed: dry mouth, generalized weakness, dysphonia, dysarthria or difficulty breathing * Includes BOTOX, Dysport DBL, Dysport and Xeomin. Data as reported in product prescribing information  

Summary of Efficacy Results Clinically meaningful treatment benefit addressing the disabling features of CD was observed in the TWSTRS-Total Score, with a mean reduction of 38% across all subjects at Week 4 In Cohort 1, with a mean dose of 174U, the majority of the treatment benefit observed at Week 4 (46% improvement) was maintained at Week 24 (33%) Clinically meaningful mean reductions in the TWSTRS Severity, Disability and Pain subscales were consistent and also observed at all time points in Cohort 1 Duration of Effect: The median duration of effect, as measured by the time for subjects to reach their Target TWSTRS Score was > 24 weeks for Cohort 1 In Cohort 1, no subjects had returned to their baseline TWSTRS-Total Score at Week 24, while only one subject in Cohort 2 to date returned to baseline, which occurred at the Week 24 visit Complete assessment of RT002 duration was limited by study duration of 24 weeks Current treatment of cervical dystonia calls for injection of botulinum toxin approximately every 3 months, or 4 times per year Clinician Global Impression of Change: > 70% Response Rate at Week 16 Observed in Cohorts 1 and 2, with majority of benefit maintained in Cohort 1 subjects at Week 24 Quality of Life: A meaningful improvement in patient-rated QoL was observed on CDIP-58 at week 4, with the majority of this benefit maintained in Cohort 1 at Week 24  

EX-99.2

Exhibit 99.2

Revance Announces Positive 24-Week Duration of Effect in Interim Results from Phase 2 Cervical Dystonia Trial

- RT002 injectable appeared to be generally safe and well-tolerated -

- RT002 injectable displayed clinically significant impact on cervical dystonia signs and symptoms -

- Revance to host conference call at 4:30 pm ET today -

NEWARK, Calif., December 12, 2016 – Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing botulinum toxin products for use in aesthetic and therapeutic indications, today announced positive interim results from its U.S. Phase 2 open-label, dose-escalating clinical study of DaxibotulinumtoxinA Injectable (RT002) to treat moderate-to-severe isolated cervical dystonia in adults, a movement disorder of the neck.

The trial enrolled 37 subjects and follows three sequential treatment cohorts for up to a total of 24 weeks after treatment for each cohort. The trial’s first cohort of 12 subjects received a single dose of up to 200 units of RT002 injectable, the second cohort of 12 subjects received between 200 and 300 units, and the third cohort received from 300 to 450 units. Later-enrolled subjects in the second and third cohorts have yet to complete the trial’s 24-week protocol. Today’s results are therefore preliminary, with final results expected in the first half of 2017.

Interim Results from the Phase 2 Cervical Dystonia trial:

• SAFETY: In all three cohorts, RT002 injectable appeared to be generally safe and well-tolerated. There were no serious adverse events and no dose-dependent increase in adverse events. The treatment-related adverse events were transient and mild to moderate in severity, except for one case of neck pain reported as severe, with a duration of 2 days. The most common adverse events were dysphagia, or difficulty in swallowing (10.8%), injection site redness (8.1%), injection site pain (5.4%), muscle tightness (5.4%) and muscle weakness (5.4%). For reference, trials for botulinum type A products approved to treat cervical dystonia have adverse events for dysphagia ranging from 13% to 39%.

• EFFICACY: The trial’s 4-week primary efficacy measurement was the improvement in dystonia symptoms as determined by reduction from baseline on the Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS)-Total score. RT002 injectable showed a clinically significant mean reduction of 16.9 from baseline, or 38%, across all three cohorts. In cohort one, with a mean dose of 174 units, the majority of the 44% reduction observed in the TWSTRS-Total score at Week 4 was preserved at Week 24, with a 33% mean reduction from baseline observed. Clinically meaningful mean reductions in the TWSTRS Severity, Disability and Pain subscales were consistent and observed at all follow-up visits in the first cohort. Later-enrolled subjects in the second and third cohorts have not yet reached the 24-week point. For reference, placebo-controlled trials with botulinum type A products approved to treat cervical dystonia had a reduction in the TWSTRS-Total score from baseline of 14% to 26% at Week 4.

• DURATION OF EFFECT: Duration of effect for this trial was defined as the number of weeks from treatment until the return of symptoms that warrant retreatment, based on the subject’s target TWSTRS score. The median duration of effect was at least 24 weeks for subjects in cohort one (n=12), and at least 16 weeks for subjects in cohort two (n=11), using the complete 16 week follow up data. In cohort one, no subjects had returned to baseline at Week 24 and only one subject in cohort two, to date, has returned to baseline, which occurred at the Week 24 visit. In cohort one, RT002 achieved a median duration of at least 24 weeks based on three different assessments, including 1) the number of weeks from treatment until a subject reaches or exceeds their target TWSTRS-Total score, 2) improvement (score >0) on the Clinician Global Impression of Change (CGIC), and 3) TWSTRS-Total score return to baseline. For reference, current treatment of cervical dystonia calls for injection of botulinum toxin approximately every 3 months, or 4 times per year.

“Patients with cervical dystonia suffer from painful, embarrassing twisting movements of the neck, often impairing their ability to work, drive and perform activities of daily living,” said lead trial investigator Dr. Joseph Jankovic, Professor of Neurology, Distinguished Chair in Movement Disorders, Founder, The Parkinson’s Disease Center and Movement Disorders Clinic (PDCMDC) Baylor College of Medicine, Houston, Texas. “The current treatment of cervical dystonia calls for injection of botulinum toxin about every 3 months, or 4 times per year, to provide patients with an improved quality of life. The preliminary data in the Phase 2 trial appears quite robust, showing marked improvements in symptoms and signs. I am particularly encouraged that in this trial RT002 exhibited a safety profile at least as good as currently marketed neurotoxins. Furthermore, with a sustained median duration of at least 24 weeks, there is a possibility that patients will require injections only two times a year. Although further studies are needed, RT002 may represent a major advance in neurotoxin technology, which should translate into more meaningful treatment outcomes in patients with cervical dystonia.”

“Cervical dystonia is an ideal therapeutic indication for testing the attributes of RT002 injectable,” said Dan Browne, President and Chief Executive Officer at Revance. “We believe these results may have broad implications for the product profile of RT002, as we have now shown long duration in both low- and high-dose indications for small and large muscles. And we’ve also shown long duration of effect in two Phase 2 trials for the treatment of glablellar lines.”

“Further, RT002 injectable, even at high doses, may deliver a strong safety profile possibly by limiting the spread of toxin, which could avoid life-altering adverse events such as general muscle weakness and difficulty swallowing,” Browne continued. “We plan to share the final safety, efficacy, and duration results in 2017 once all cohorts have completed the 24-week assessment period. We then intend to seek regulatory advice from US and EU health authorities to determine the next steps in this clinical program.”

The abstract for this Phase 2 clinical trial of RT002 injectable to treat cervical dystonia was submitted to the Toxins 2017 (January 18-21, Madrid, Spain) meeting and has been accepted for presentation. Study investigator Cynthia L. Comella, MD, Professor in the Department of Neurological Sciences at Rush University Medical Center, Chicago, Illinois, is scheduled to present.

Phase 2 Study Design

Revance’s Phase 2 trial is an open-label, sequential, dose-escalating study to evaluate the safety, preliminary efficacy and duration of effect of a single treatment of DaxibotulinumtoxinA Injectable (RT002) for isolated cervical dystonia. Thirty-seven subjects with at least moderate cervical dystonia were enrolled at multiple sites in the United States. There are three treatment groups of 12, 12 and 13 subjects, respectively, each subject treated with one of three dose levels of RT002 injectable.

The primary efficacy endpoint of the Phase 2 study is an improvement in dystonia symptoms as measured by change (reduction) from baseline in Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) total score at four weeks. TWSTRS is a composite scale that covers different features of the cervical dystonia condition. The first part of the scale is based on the physical findings and severity of dystonia, the second part rates the patient’s perceived level of disability, and the third part rates the pain. The study protocols also feature a number of secondary efficacy endpoints, including duration of effect and patient-rated quality of life as measured by change from baseline in Cervical Dystonia Impact Profile (CDIP).

All subjects are followed out to nine weeks, after treatment. Subjects with sustained improvement after this initial period of nine weeks continue to be assessed for duration of efficacy and other measures until they return to baseline or for up to a total of 24 weeks after treatment.

Conference Call

Revance management will host a conference call and webcast today at 4:30 pm ET. Individuals interested in listening to the conference call today, December 12, at 1:30 pm PT/4:30 pm ET may do so by dialing (855) 453-3827 for domestic callers, or (484) 756-4301 for international callers and reference conference ID: 37266728; or from the webcast link in the investor relations section of the Company’s website at: www.revance.com. In addition, key data slides on the Phase 2 interim trial results will be discussed on the conference call and are posted to Revance’s website on the INVESTORS tab in the Presentations and Corporate Materials section.

A replay of the call will be available beginning December 12, 2016 at 4:30 pm PT/7:30 pm ET through 7:30 pm ET on December 13, 2016. To access the replay, dial (855) 859-2056 or (404) 537-3406 and reference Conference ID: 37266728. The webcast will be available in the investor relations section on the Company’s website for 30 days following the completion of the call.

About Cervical Dystonia

According to the Dystonia Medical Research Foundation, whose mission is to advance research, promote awareness and education, and support the needs affected individuals, cervical dystonia is a painful condition in which the neck muscles contract involuntarily, causing abnormal movements and awkward posture of the head and neck. The movements may be sustained (tonic), jerky (clonic), or a combination. Cervical dystonia (also referred to as spasmodic torticollis) may be primary (meaning that it is the only apparent neurological disorder, with or without a family history) or may be brought about by secondary causes (such as physical trauma). It can result in considerable pain and discomfort.

Treatments for cervical dystonia include oral medications, botulinum toxin injections, surgery, and complementary therapies. Botulinum toxin can help block the communication between the nerve and the muscle and may alleviate abnormal movements and postures. Current botulinum toxin treatments for cervical dystonia have a duration of effect of approximately three months. Cervical dystonia can occur at any age, although most individuals first experience symptoms in middle age. It affects several hundred thousand adults and children in the United States alone. Revance estimates the global market for treating muscle movement disorders with botulinum toxins, including cervical dystonia, was nearly $1 billion in 2015.

About Revance Therapeutics, Inc.

Revance, a Silicon Valley-based biotechnology company, is committed to the advancement of remarkable science. The company is developing a portfolio of products for aesthetic medicine and underserved therapeutic specialties, including dermatology, orthopedics and neurology. Revance’s science is based upon a proprietary TransMTS^® peptide technology, which when combined with active drug molecules, may help address current unmet needs.

Revance’s initial focus is on developing daxibotulinumtoxinA, the company’s highly purified botulinum toxin, for a broad spectrum of aesthetic and therapeutic indications, including facial wrinkles and muscle movement disorders. The company’s lead drug candidate, DaxibotulinumtoxinA for Injection (RT002), is currently in development for the treatment of glabellar lines, cervical dystonia and plantar fasciitis with the potential to be the first long-acting neurotoxin. The company holds worldwide rights for all indications of RT002 injectable and RT001 topical and the pharmaceutical uses of the TransMTS technology platform. More information on Revance may be found at www.revance.com.

“Revance Therapeutics,” TransMTS^®, “Remarkable Science Changes Everything,” and the Revance logo are registered trademarks of Revance Therapeutics, Inc.

Forward Looking Statements

This press release contains forward-looking statements, including statements related to the process and timing of, and ability to complete, current and anticipated future clinical development of our investigational drug product candidates, including but not limited to initiation and design of clinical studies for current and future indications, related results and reporting of such results; statements about our business strategy, timeline and other goals and market for our anticipated products, plans and prospects; and statements about our ability to obtain regulatory approval; and potential benefits of our drug product candidates and our technologies.

Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from our expectations. These risks and uncertainties include, but are not limited to: the outcome, cost, and timing of our product development activities and clinical trials; the uncertain clinical development process, including the risks that interim results are not indicative of final results and that clinical trials may not have an effective design or generate positive results; our ability to obtain and maintain regulatory approval of our drug product candidates; our ability to obtain funding for our operations; our plans to research, develop, and commercialize our drug product candidates; our ability to achieve market acceptance of our drug product candidates; unanticipated costs or delays in research, development, and commercialization efforts; the applicability of clinical study results to actual outcomes; the size and growth potential of the markets for our drug product candidates; our ability to successfully commercialize our drug product candidates and the timing of commercialization activities; the rate and degree of market acceptance of our drug product candidates; our ability to develop sales and marketing capabilities; the accuracy of our estimates regarding expenses, future revenues, capital requirements and needs for financing; our ability to continue obtaining and maintaining intellectual property protection for our drug product candidates; and other risks. Detailed information regarding factors that may cause actual results to differ materially from the results expressed or implied by statements in this press release may be found in Revance’s periodic filings with the Securities and Exchange Commission (the “SEC”), including factors described in the section entitled “Risk Factors” of our quarterly report on Form 10-Q filed November 4, 2016.

These forward-looking statements speak only as of the date hereof. Revance disclaims any obligation to update these forward-looking statements.

###

Contacts

Investors:

Revance Therapeutics

Jeanie Herbert

(714) 325-3584

jherbert@revance.com

Burns McClellan

Ami Bavishi

212-213-0006

abavishi@burnsmc.com

Trade Media:

Nadine Tosk

504.453.8344

nadinepr@gmail.com